IMPRO - Innovative management for patients with stable chest pain occurring for the first time
Background
You are surely familiar with the challenge of quickly and reliably determining whether patients with new-onset chest pain have coronary heart disease (CHD). This decision is often of great importance for further treatment and the well-being of patients.
IMPRO, a nationwide study addressing precisely this issue, will begin in fall 2025. The aim is to investigate a new approach to CHD diagnosis and follow-up care.
Study design
Patients with relevant symptoms will be monitored in two phases:
In the control phase, you will treat your patients with newly occurring chest pain who you suspect may have CHD according to your usual procedure.
In the intervention phase, the new interdisciplinary method for diagnosis and further care in some cases involving a coronary CT scan—is applied.
The study will start in October 2025 with a 3-month preparatory phase. The main study will begin in Q1 2026 and will end for all practices by March 31, 2027, at the latest.
At the end of the two phases, both care pathways will be compared to determine which one proves more effective in the long term.
Objective
The objective is to improve primary and cross-sector care for patients with new-onset chest pain and suspected coronary heart disease (CHD). The aim is to investigate whether the new form of care helps to reduce cardiovascular events such as heart attacks and strokes. At the same time, the implementation of coronary CT in clinical practice should optimize diagnostics and prevent over-treatment.
Promotion and cooperation
The study is funded by the Federal Joint Committee (G-BA) as part of its promotion of new forms of care and is being conducted in cooperation with 16 institutes of general medicine, among others. A total of 320 general practices from 12 federal states are planned to participate in this study.
Why should you participate?
The study offers a unique opportunity to actively contribute to improving KHK care in Germany. The results could bring about far-reaching changes in KHK care and the associated care structures.
Are you interested?
Would you like to participate, do you have any questions, or would you like to learn more about the IMPRO study?
Then please feel free to contact us.
Contact
contact information
- telephone: +49 551 3969668
- fax: +49 551 3929530
- e-mail address: linda.hoffmeister(at)med.uni-goettingen.de
contact information
- telephone: +49 551 3965574
- fax: +49 551 3929530
- e-mail address: tanja.albrecht-nock(at)med.uni-goettingen.de
Studienkoordinatorin
contact information
- telephone: +49 551 3968194
- fax: +49 551 3929530
- e-mail address: dunja.piper(at)med.uni-goettingen.de